Paper - WANFANG MED ONLINE

You Position: Home > Paper

The molecular physiological and genetic mechanisms underlying the superb efficacy of quinolones

( views:74, downloads:0 )

Author:: No author available

Journal Title:: Acta Pharmaceutica Sinica

Issue:: 8

DOI:: No doi available

Key Word:: 喹诺酮类药物;SOS应答;毒素-抗毒素系统;细菌程序性死亡;染色体片段化;活性氧簇

Abstract：氟喹诺酮类药物是目前使用最广泛的广谱抗生素,占据了全球抗生素类药物市场约18％的份额.其杀菌快速,而且具备大量的衍生物库,为药物更新换代提供了良好的基础.但这些衍生物在杀菌的速度、代谢过程中对氧需求、对蛋白合成的依赖性等方面的差异很大.从药物作用后细菌分子遗传层面的应答特征揭示各类衍生物的深层次作用机制,可以为寻找更有效的新喹诺酮类药物提供坚实基础.SOS应答、毒素-抗毒素系统,细菌程序性死亡、染色体片段化以及活性氧簇等新机制可能不同程度参与了喹诺酮类药物的杀菌过程.本文重点介绍喹诺酮作用的“二步特征”.该特征的引入有助于理解不同喹诺酮类药物的杀菌特征,也有助于开发新的喹诺酮类药物.

Reference

[1]李江波,林瑞森,俞庆森,等.喹诺酮类抗菌剂构效关系研究：母核变化对活性的影响[J].1998,(7).
[2]Drlica K,Sindelar G,Dong Y,etc.Mutant prevention concentration as a measure of fluoroquinolone potency against mycobacteria.[J].2000,44(12).
[3]B M, Howard,R J, Pinney,J T, Smith.4-Quinolone bactericidal mechanisms.[J].1993,43.
[4]Chen Xu,Xilin Zhao,John Domagala.DNA topoisomerase targets of the fluoroquinolones: A strategy for avoiding bacterial resistance[J].1997,94(25).
[5]L J, Piddock,R N, Walters.Bactericidal activities of five quinolones for Escherichia coli strains with mutations in genes encoding the SOS response or cell division.[J].1992,36.
[6]Chen CR.,Snyder M.,Drlica K.,etc.Dna Gyrase and Topoisomerase IV on the Bacterial Chromosome - Quinolone-Induced Dna Cleavage[J].1996,258(4).
[7]Hideo Ikeda.Illegitimate recombination: Role of type II DNA topoisomerase[J].1986,21(1).
[8]Malik M,Wang X,Drlica K,etc.Contribution of reactive oxygen species to pathways of quinolone-mediated bacterial cell death.[J].2010,65(3).
[9]A, Morrison,N P, Higgins,N R, Cozzarelli.Interaction between DNA gyrase and its cleavage site on DNA.[J].1980,255.
[10]Hiasa H.The Glu-84 of the ParC Subunit Plays Critical Roles in Both Topoisomerase IV-Quinolone and Topoisomerase IV-DNA Interactions.[J].2002,41(39).
[11]Wentzell LM.,Maxwell A..The complex of DNA gyrase and quinolone drugs on DNA forms a barrier to the T7 DNA polymerase replication complex[J].2000,304(5).
[12]L J, Piddock,R N, Walters,J M, Diver.Correlation of quinolone MIC and inhibition of DNA, RNA, and protein synthesis and induction of the SOS response in Escherichia coli.[J].1990,34.
[13]Zechiedrich EL,Cozzarelli NR,Khodursky AB.Topoisomerase IV is a Target of Quinolones in Escherichia Coli[J].1995,92(25).
[14]E, Cambau,F, Bordon,E, Collatz,etc.Novel gyrA point mutation in a strain of Escherichia coli resistant to fluoroquinolones but not to nalidixic acid.[J].1993,37.
[15]Malik M,Drlica K.Moxifloxacin lethality against Mycobacterium tuberculosis in the presence and absence of chloramphenicol.[J].2006,50(8).
[16]S M, Palmer,M J, Rybak.Pharmacodynamics of once- or twice-daily levofloxacin versus vancomycin, with or without rifampin, against Staphylococcus aureus in an in vitro model with infected platelet-fibrin clots.[J].1996,40.
[17]Kelley WL.Lex marks the spot: the virulent side of SOS and a closer look at the LexA regulon[J].2006,62(5).
[18]Osheroff N,Gootz TD,Anderson VE,etc.Quinolones inhibit DNA religation mediated by Staphylococcus aureus topoisomerase IV. Changes in drug mechanism across evolutionary boundaries.[J].1999,274(50).
[19]Kreuzer KN,Pohlhaus JR.Norfloxacin-induced DNA gyrase cleavage complexes block Escherichia coli replication forks, causing double-stranded breaks in vivo[J].2005,56(6).
[20]Hiasa H,Shea ME.The RuvAB branch migration complex can displace topoisomerase IV.quinolone.DNA ternary complexes.[J].2003,278(48).
[21]G C, Crumplin,J T, Smith.Nalidixic acid: an antibacterial paradox.[J].1975,8.
[22]Malik M,Hussain S,Shi L.In vitro model of mycobacterial growth arrest using nitric oxide with limited air.[J].2009,53(1).
[23]Filee J,Gadelle D,Buhler C,etc.Phylogenomics of type II DNA topoisomerases.[J].2003,25(3).
[24]E, Maguin,J, Lutkenhaus,R, D'Ari.Reversibility of SOS-associated division inhibition in Escherichia coli.[J].1986,166.
[25]J J, Champoux.DNA topoisomerases: structure, function, and mechanism.[J].2001,70.
[26]M, Snyder,K, Drlica.DNA gyrase on the bacterial chromosome: DNA cleavage induced by oxolinic acid.[J].1979,131(2).
[27]Yoshida.Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli.[J].1990,34.
[28]Leo E,Gould KA,Pan XS,etc.Novel symmetric and asymmetric DNA scission determinants for Streptococcus pneumoniae topoisomerase IV and gyrase are clustered at the DNA breakage site[J].2005,280(14).
[29]C S, Lewin,B M, Howard,J T, Smith.Protein- and RNA-synthesis independent bactericidal activity of ciprofloxacin that involves the A subunit of DNA gyrase.[J].1991,34.
[30]Critchlow SE,Maxwell A.Dna Cleavage is Not Required for the Binding of Quinolone Drugs to the Dna Gyrase - Dna Complex[J].1996,35(23).
[31]J, Kato,H, Suzuki,H, Ikeda.Purification and characterization of DNA topoisomerase IV in Escherichia coli.[J].1992,267.
[32]Gerdes K,Christensen SK,Lobner-Olesen A.Prokaryotic toxin-antitoxin stress response loci[J].2005,3(5).
[33]Y P, Tsao,A, Russo,G, Nyamuswa,etc.Interaction between replication forks and topoisomerase I-DNA cleavable complexes: studies in a cell-free SV40 DNA replication system.[J].1993,53.
[34]Bergerat A,Wang JC,Buhler C,etc.Reconstitution of DNA topoisomerase VI of the thermophilic archaeon Sulfolobus shibatae from subunits separately overexpressed in Escherichia coli.[J].1998,26(22).
[35]L G, Wayne,L G, Hayes.An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence.[J].1996,64.
[36]Barnard FM,Maxwell A.Interaction between DNA gyrase and quinolones: effects of alanine mutations at GyrA subunit residues Ser(83) and Asp(87).[J].2001,45(7).
[37]S T, Cole,R, Brosch,J, Parkhill,etc.Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence.[J].1998,393.
[38]Zhao X,Drlica K,Malik M.Lethal fragmentation of bacterial chromosomes mediated by DNA gyrase and quinolones[J].2006,61(3).
[39]A. Worcel,E. Burgi.On the structure of the folded chromosome of Escherichia coli[J].1972,71(2).
[40]Drlica K,Singh A,Zhao X,etc.Lethality of quinolones against Mycobacterium smegmatis in the presence or absence of chloramphenicol.[J].2005,49(5).
[41]Heddle J,Maxwell A.Quinolone-binding pocket of DNA gyrase: role of GyrB.[J].2002,46(6).
[42]Hussain S,Drlica K,Malik M.Effect of anaerobic growth on quinolone lethality with Escherichia coli.[J].2007,51(1).
[43]Hiasa H,Shea ME.Distinct effects of the UvrD helicase on topoisomerase-quinolone-DNA ternary complexes.[J].2000,275(19).
[44]Lewin C. S.,Morrissey I.,Smith J. T..The bactericidal activity of sparfloxacin[J].1992.
[45]Kampranis SC,Maxwell A.Conformational changes in DNA gyrase revealed by limited proteolysis.[J].1998,273(35).
[46]Engelberg Kulka H,Hazan R,Amitai S.mazEF: a chromosomal toxin-antitoxin module that triggers programmed cell death in bacteria.[J].2005,118(Pt.19).
[47]Stein RA,Higgins NP,Deng S.Organization of supercoil domains and their reorganization by transcription[J].2005,57(6).
[48]M, Gellert,K, Mizuuchi,M H, O'Dea,etc.Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity.[J].1977,74.
[49]Cindy Levine,Kenneth J. Marians,Hiroshi Hiasa.DNA gyrase and topoisomerase IV: biochemical activities, physiological roles during chromosome replication, and drug sensitivities[J].1998,1400(1).
[50]Zhou J,Drlica K,Dong Y,etc.Killing of Staphylococcus aureus by C-8-methoxy fluoroquinolones.[J].1998,42(4).
[51]Zhao X,Wang X.Contribution of oxidative damage to antimicrobial lethality.[J].2009,53(4).
[52]K, Mizuuchi,L M, Fisher,M H, O'Dea,etc.DNA gyrase action involves the introduction of transient double-strand breaks into DNA.[J].1980,77.
[53]W A, GOSS,W H, DEITZ,T M, COOK.Mechanism of Action of Nalidixic Acid on Escherichia Coli.II. Inhibition of Deoxyribonucleic Acid Synthesis.[J].1965,89.
[54]Yasuyuki Ogata,Hideo Ikeda,Kouya Shiraishi.Illegitimate Recombination Mediated by Double-Strand Break and End-Joining in Escherichia Coli[J].2004,38(0).
[55]C S, Lewin,B M, Howard,N T, Ratcliffe,etc.4-quinolones and the SOS response.[J].1989,29.
[56]C J, Willmott,S E, Critchlow,I C, Eperon,etc.The complex of DNA gyrase and quinolone drugs with DNA forms a barrier to transcription by RNA polymerase.[J].1994,242(4).
[57]J H, Morais Cabral,A P, Jackson,C V, Smith,etc.Crystal structure of the breakage-reunion domain of DNA gyrase.[J].1997,388(6645).
[58]Hiasa H,Shea ME.Interactions between DNA helicases and frozen topoisomerase IV-quinolone-DNA ternary complexes.[J].1999,274(32).
[59]Zhao X,Li X,Malik M,etc.Lethal action of quinolones against a temperature-sensitive dnaB replication mutant of Escherichia coli.[J].2006,50(1).
[60]Fisher LM,Aubry A,Jarlier V,etc.First functional characterization of a singly expressed bacterial type II topoisomerase: the enzyme from Mycobacterium tuberculosis.[J].2006,348(1).
[61]Marians KJ.,Hiasa H..Mechanism of Quinolone Action - a Drug-Induced Structural Perturbation of the Dna Precedes Strand Cleavage by Topoisomerase IV[J].1997,272(14).
[62]Y H, Hsiang,M G, Lihou,L F, Liu.Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin.[J].1989,49.
[63]Y, Shanado,J, Kato,H, Ikeda.Escherichia coli HU protein suppresses DNA-gyrase-mediated illegitimate recombination and SOS induction.[J].1998,3(8).